Best Biopharma Outsourcing Companies in Netherlands
The 109 best Biopharma Outsourcing companies in Netherlands in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Batavia Biosciences.
Tracking the strongest Biopharma Outsourcing companies in Netherlands by disclosed equity funding, this directory covers 109 ventures with a combined $121M raised. That's a concentrated pool. Batavia Biosciences leads at $40M, a figure that dwarfs most peers, with RiboPro ($4M) and Intravacc ($3M) rounding out the meaningful tier. The global market behind all this activity sits at roughly $28.7B in 2024, forecast to reach $112.3B by 2032 at a 5.8% CAGR, driven by biologics demand and the rising cost of keeping drug development in-house. So when you see Dutch outsourcers pulling institutional backing from EIC Fund and Brightlands Venture Partners, it fits the global pattern exactly.
Coverage of the sector is tightening, with clinical trial outsourcing and operational resilience emerging as the themes investors keep circling back to. I'd note there are zero unicorns in the 109 tracked here, which tells you the Netherlands cluster is still early-stage, not mature. Regulatory compliance pressure is real and it's pushing more sponsors toward specialist CROs rather than building capacity internally. And with rising drug development costs compressing margins at every point in the chain, outsourcing isn't a convenience anymore. It's arithmetic.
- ResearchAndMarkets.com
Our analysis of 100 Biopharma Outsourcing companies
$10.3b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in Netherlands
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Batavia Biosciences Biologics CDMO offering proprietary process development technologies for the development of recombinant… | $40M | 37 mo ago | Acquired | Menzo Havenga President & CEO | 2010 | WordPressZohoMySQL+22 | 8 patents Adenovirus-based gene delivery vectors for therapeutic and vaccine applications | — |
| 2 | OctoPlus Company specializing in formulation and process development of complex injectables | $28M | 169 mo ago | Acquired | Joost Holthuis Co-Founder | 1995 | — | 27 patents Peptide antimicrobial agents and controlled‑release biologic formulations using purified microparticles | — |
| 3 | Lead Pharma Small molecules therapeutics against cancer and autoimmune diseases | $27M | 113 mo ago | Early Stage | — | 2007 | WordPressMySQLPHP+16 | 228 patents Small‑molecule modulators of ERRα and RORγ nuclear receptors for therapeutic use | — |
| 4 | CR2O Clinical development partner offering a range of services, including clinical trial management, to support… | $8M | 70 mo ago | Funding Raised | — | 2012 | — | — | — |
| 5 | RiboPro Online supplier and developer of RNA based products | $4M | 29 mo ago | Series A | Alexander van Asbeck Co-Founder & CEO | 2020 | WordPressMySQLPHP+12 | 34 patents Manufacturing capped mRNA therapeutics and ionizable lipid nanoparticle delivery systems | 1 job opening |
| 6 | Intravacc Provider of vaccine development services | $3M | 29 mo ago | Funding Raised | — | 2012 | TYPO3 CMSPHPTailwind CSS+8 | 27 patents Production and formulation of outer membrane vesicle-based vaccines, especially nasal immunizations | 2 partnerships |
| 7 | Micreos Group Provider of pharmaceutical research services | $3M | 83 mo ago | Funding Raised | Mark Offerhaus Founder | 2022 | — | 27 patents Bacteriophage applications for food safety and animal health biocontrol | — |
| 8 | GENEUSBIOTECH Provider of research, development, and manufacturing services for small molecule drugs | $2M | 43 mo ago | Funding Raised | — | 2020 | — | — | — |
| 9 | Catalyze Provider of business development, project management, and other consulting services to biopharma sector | $1M | 58 mo ago | Funding Raised | — | 2019 | WordPressMySQLPHP+21 | — | — |
| 10 | OcellO 3D screening services for drug discovery | $775K | 65 mo ago | Acquired | — | 2011 | — | 27 patents Therapeutic peptide/oligo binding agents targeting cancer cell growth | — |
| 11 | InnoCore Pharma Provider of pre-clinical drug delivery formulation services | $656K | 132 mo ago | Funding Raised | — | 2003 | WordPressMySQLPHP+18 | — | — |
| 12 | QVQuality Biotech company that specializes in developing and providing single-domain antibody fragments for research… | $598K | 76 mo ago | Funding Raised | — | 2010 | WordPress Block EditorWordPressMySQL+15 | — | — |
| 13 | PharmaCell Provider of cell therapy and regenerative medicine CDMO | $504K | 125 mo ago | Acquired | — | 2005 | — | — | — |
| 14 | TROPIQ Health Sciences Barcoded live insect screening technology | $464K | 52 mo ago | Funding Raised | Koen Dechering Cofounder and VP of business development | 2012 | — | 16 patents Patents concentrated in health & consumer products | — |
| 15 | SeraNovo Developer of molecules and protein degraders for drug absorption | $400K | 74 mo ago | Funding Raised | — | 2017 | WordPressMySQLPHP+23 | 9 patents Oral drug formulation using deep eutectic solvent excipient platforms for enhanced solubility | 2 launchs |
| 16 | EXIT071 Provider of microfluidic technology development services | $396K | 38 mo ago | Seed | Thomas Hankemeier Co-Founder & Scientific Advisor | 2021 | — | 2 patents Isolation and purification techniques for extracellular vesicles | 1 internship |
| 17 | VUS Diagnostics Provider of diagnostics services for genetic diseases and drug development programs | $322K | 31 mo ago | Early Stage | Simon Sorensen Co-Founder | 2022 | — | — | — |
| 18 | Abundnz Analytical services for the life sciences | $116K | 131 mo ago | Funding Raised | Robert-Jan Lamers Founder & Director | 2011 | — | — | — |
Top 12 Biopharma Outsourcing companies in Netherlands
#1
Acquired · Leiden, South Holland · founded 2010 · 11 employees$40.4Mraised▾
Batavia Biosciences is a CDMO engaged in the development of biopharmaceutical products such as proteins, antibodies, vaccines and viral vectors. They have a portfolio of technologies for improving product yield (STEP®), to reduce process development time (SIDUS®, SCOUT®) and for improving product stability. Their STEP technology is a plasmid based expression platform that enables rapid mammalian CHO cell line generation and improved protein expression. Batavia claims that the STEP platform can offer up to 10-fold increase in protein expression and the stable cell clones can be generated in 14 weeks. They also have a transient production technology that can be used for producing clinical material (proteins) faster. The company claims to have expertise in upstream (mammalian, microbial and insect based platforms) and downstream processing, clinical and commercial manufacturing and also in DNA cloning and mammalian cell line generation.
- May 2023Grant (prize money)$444.3K
- Sep 2019Grant (prize money)$6.5M
- Jul 2019Grant (prize money)$2.2M
- Feb 2019Grant (prize money)$13.2M
#2
Series A · Oss, North Brabant · founded 2020 · 30 employees$3.5Mraised▾
RiboPro is an online supplier and developer of messenger RNA, long non-coding RNA, and other RNA products. The platform offers tools to synthesize customized mRNA or IncRNA products. It offers off-the-shelf mRNa products such as eGFP mRNA and PLuc mRNA products for research application.
- Jan 2024Convertible Debt$2.1M
- Jun 2023Series A—
- Mar 2021Seed$1.4M
#3
Funding Raised · Bilthoven, Utrecht · founded 2012 · 140 employees$3.2Mraised▾
Provider of vaccine development services. It develops a bacterial and viral vaccine through the Vero cell line, also developing conjugation, and adjuvants. It also offers assay development and vaccine characterization services, pilot-scale facility, and 3R research in animal models. The company has platforms that include OMV technology, Vero cell, and iBoost technology.
- Jan 2024Grant (prize money)$633K
- Jul 2022Grant (prize money)$2.6M
#4
Early Stage · Amsterdam, North Holland · founded 2022$322Kraised▾
VUS Diagnostics is a company based in Amsterdam, Netherlands. They offer services in the field of cell model services, including clonal cell models using gene editing expertise. They also provide support for drug development programs, particularly in the areas of rare genetic diseases and gene variant testing.
- Nov 2023Convertible Debt$322K
#5
Funding Raised · Netherlands · founded 2020 · 11 employees$2.4Mraised▾
Provider of biotechnology services intended to make fur and wool molecularly identical to conventional wool and fur. The company uses patented cellular agriculture technology for contract research on hair, and biopolymers, it also holds various patents to produce cell-based fur and wool, caviar, and cell-based woods, enabling clients to do biotechnology research on various data and cells.
- Nov 2022Grant (prize money)$2.4M
#6
Seed · Leiden, South Holland · founded 2021 · 4 employees$396.2Kraised▾
Developer of biological analysis technology for the analysis of novel biomarkers exosomes intending to make diagnostics more specific. The company develops to provide methods for clinical research in therapeutics and diagnostics based on its patented microfluidic technology, enabling researchers to analyze extracellular vesicles, including exosomes that send messages to other cells.
- Apr 2023Grant (prize money)$204K
- Jun 2022Grant (prize money)$79.8K
- Feb 2022Seed$396.2K
#7
Funding Raised · Maarssen, Utrecht · founded 2012 · 17 employees$7.9Mraised▾
CR2O is a clinical development partner that offers a range of services to support the product development lifecycle. They provide full-service clinical trial solutions, from pre-clinical to clinical development, to help pharmaceutical and biotechnology companies bring their products to market. With expertise in analytical chemistry and clinical trial operations, CR2O helps clients navigate the complexities of product development and commercialization.
- Aug 2020Grant (prize money)$4M
- Mar 2020Grant (prize money)$2M
- Jan 2020Grant (prize money)$2M
#8
Funding Raised · Amsterdam, North Holland · founded 2019 · 139 employees$1.1Mraised▾
Provider of business development, project management, and other consulting services to biopharma sector
- Aug 2021Grant (prize money)$188.9K
- Apr 2021Grant (prize money)$343.1K
- Jan 2020Grant (prize money)$273.4K
- Jan 2019Grant (prize money)$288K
#9
Early Stage · Nijmegen, Gelderland · founded 2007 · 42 employees$27.4Mraised▾
Lead Pharma is a company that discovers, develops and commercializes innovative therapeutics against cancer and autoimmune diseases. It currently has three key programs in development: novel inhibitors of RORyt (immunology target); small molecule drugs targeting estrogen-related receptor α (ERRα) (regulator of energy metabolism); LXR agonists critical for cholesterol metabolism and (reverse) transport, lipogenesis, glucose homeostasis, inflammation and innate immunity. Lead Pharma´s approach has been validated by a partnership with Sanofi covering the entire lead program RORyt. The company expects to close one or two additional development partnerships for its programs with pharma companies.
#10
Acquired · Leiden, South Holland · founded 1995$28.3Mraised▾
Company specializing in formulation and process development of complex injectables
#11
Funding Raised · Nijmegen, Gelderland · founded 2012 · 15 employees$463.9Kraised▾
TROPIQ Health Sciences offers high throughput screening services for the discovery & development of vector control agents and antimalarials. The company offers services such as live insect barcoded screening, In vitro high throughput assays for asexual blood stages, gametocytes, oocysts, & sporozoite. The company also offers monoclonal antibodies.
- Feb 2022Grant (prize money)$2.1K
- Feb 2017Grant (prize money)$461.8K
#12
Acquired · Leiden, South Holland · founded 2011 · 31 employees$774.6Kraised▾
OcellO is a CRO that provides 3D screening services for drug discovery. It has a proprietary high throughput system for 3D imaging and phenotypic profiling that enables better quantification of complex biological phenomena combined with clinically relevant endpoints. Based on this platform, the company offers several drug screening and discovery services, including development of target-specific and immuno-oncology assays for screening drugs, phenotypic screening in disease models of interest and compound profiling, as well as a specialized drug candidate testing platform for polycystic kidney disease. In addition, OcellO offers in vitro 3D cell culture assays of patient-derived xenograft (PDX) mouse models for lead optimization, in partnership with Charles River Laboratories.
- Jan 2021Grant (prize money)$325.7K
- Feb 2018Grant (prize money)$289.2K
- Sep 2017Grant (prize money)$159.7K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.